# US 2022/0008334 A1 · Gastric retentive devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008334 A1
- Document ID: US20220008334A1
- Status: Published application
- Kind: A1
- Application number: 17/479,131
- Filed: 2021-09-20
- Published: 2022-01-13
- Earliest claimed: 2015-12-01
- Assignees: Clexio Biosciences Ltd.
- Applicants: Clexio Biosciences Ltd.
- Inventors: Ilan ZALIT; Avshalom BEN MENACHEM
- Web page: https://patentgrep.com/patent/US20220008334A1

## CPC

- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- B29C 45/0001: {characterised by the choice of material}
- A61M 2207/00: Methods of manufacture, assembly or production
- A61M 2210/1053: Stomach
- B29K 2001/08: {Cellulose derivatives}
- B29K 2105/0035: {Medical or pharmaceutical agents}
- B29K 2105/0038: {Plasticisers}
- B29K 2105/0094: {having particular viscosity}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- B29C: SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING (making preforms B29B11/00; making laminated products by combining previously unconnected layers which become one product whose layers will remain together B32B37/00 - B32B41/00)
- B29K: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR {MOULDS, } REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS

## Abstract

Provided are devices that are configured for gastric retention for a period of at least six hours (or at least three hours if the subject is in the fasted state) while maintaining their structural integrity and releasing or holding an active or diagnostic agent into or in gastric fluid of a human subject over that period, as well as methods of delivering an agent over an extended period by orally administering such devices to a subject, uses of an enteric polymer in the formation of devices that deliver an agent over an extended period of time, and methods of making such devices.

## Claims

### Claim 1

A gastric retentive device comprising a carrier portion comprising at least two subparts and an active or diagnostic agent;
wherein the active or diagnostic agent comprises part of at least one of the subparts, and the subpart partially comprising the active or diagnostic agent is configured to release the active or diagnostic agent into a subject's gastric environment following administration of the device thereto;
wherein the carrier portion is coated with a polymer coating on its outer surface;
wherein when the device is in a collapsed configuration, the subpart partially comprising the active or diagnostic agent is in a closed configuration that is sized and shaped for oral administration;
wherein when the device is in an expanded configuration, the subpart partially comprising the active or diagnostic agent is shaped, sized, or both shaped and sized, such that the device does not pass through a pylorus; and,
wherein upon separation from the carrier portion, the subparts are individually sized or shaped to pass through the pylorus.

### Claim 2 (depends on 1)

The device of claim 1, wherein the polymer coating comprises a polymethacrylate-based copolymer, a hydroxypropylmethylcellulose acetate succinate polymer, cellulose acetate, or a combination thereof.

### Claim 3 (depends on 1)

The device of claim 1, wherein the polymer coating further comprises a plasticizer.

### Claim 4 (depends on 3)

The device of claim 3, wherein the plasticizer is dibutyl sebacate, triacetin, triethyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, polyethylene glycol, polyethylene glycol monomethyl ether, glycerin, sorbitol, sorbitan, castor oil, diacetylated monoglycerides, tributyl citrate, or a combination thereof.

### Claim 5 (depends on 3)

The device of claim 3, wherein the plasticizer comprises between about 5 and about 26% of the weight of the polymer coating.

### Claim 6 (depends on 1)

The device of claim 1, wherein the polymer coating thickness is from about 10 μm to about 200 μm.

### Claim 7 (depends on 1)

The device of claim 1, wherein the percent weight gain of the device as a result of the polymer coating is from about 1% to about 10%.

### Claim 8 (depends on 1)

The device of claim 1, wherein the subpart is in the expanded configuration for at least six hours.

### Claim 9 (depends on 1)

The device of claim 1, wherein the separation is configured to occur when at least 50% of the active or diagnostic agent has been released from the device into the gastric environment, upon exposure of the device to the gastric environment.

### Claim 10 (depends on 1)

The device of claim 1, wherein the active or diagnostic agent is configured to release from the device over a time period of 3 to 24 hours, upon exposure of the device to the gastric environment.

### Claim 11 (depends on 1)

The device of claim 1, wherein the drug or diagnostic agent is configured to release from the device over a time period of about 3 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 14 hours, about 16 hours, about 18 hours, about 20 hours, about 22 hours, about 24 hours, about 28 hours, about 30 hours, about 32 hours, about 34 hours, about 36 hours, about 40 hours, about 44 hours, about 48 hours, about 60 hours, or about 72 hours.

### Claim 12 (depends on 1)

The device of claim 1, wherein the active or diagnostic agent comprises an active pharmaceutical ingredient, or pharmaceutical salt thereof, selected from the list comprising prochlorperazine edisylate, ferrous sulfate, albuterol, aminocaproic acid, mecamylamine hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzphetamine hydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, metformin, methylphenidate hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethylperazine maleate, anisindione, diphenadione erythrityl tetranitrate, digoxin, isoflurophate, acetazolamide, nifedipine, methazolamide, bendroflumethiazide, chlorpropamide, glipizide, glyburide, gliclazide, tobutamide, chlorproamide, tolazamide, acetohexamide, troglitazone, orlistat, bupropion, nefazodone, tolazamide, chlormadinone acetate, phenaglycodol, allopurinol, aluminum aspirin, methotrexate, acetyl sulfisoxazole, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, dexamethasone, betamethasone, triamcinolone, methyltestosterone, 17-β-estradiol, ethinyl estradiol, ethinyl estradiol 3-methyl ether, prednisolone, 17-β-hydroxyprogesterone acetate, 19-nor-progesterone, norgestrel, norethindrone, norethisterone, norethiederone, progesterone, norgesterone, norethynodrel, terfandine, fexofenadine, aspirin, acetaminophen, indomethacin, naproxen, fenoprofen, sulindac, indoprofen, nitroglycerin, isosorbide dinitrate, propranolol, timolol, atenolol, alprenolol, cimetidine, clonidine, imipramine, levodopa, selegiline, chlorpromazine, methyldopa, dihydroxyphenylalanine, calcium gluconate, ketoprofen, ibuprofen, cephalexin, erythromycin, haloperidol, zomepirac, ferrous lactate, vincamine, phenoxybenzamine, diltiazem, milrinone, captropril, mandol, quanbenz, hydrochlorothiazide, ranitidine, flurbiprofen, fenbufen, fluprofen, tolmetin, alclofenac, mefenamic, flufenamic, difuninal, nimodipine, nitrendipine, nisoldipine, nicardipine, felodipine, lidoflazine, tiapamil, gallopamil, amlodipine, mioflazine, lisinopril, enalapril, captopril, ramipril, enalaprilat, famotidine, nizatidine, sucralfate, etintidine, tetratolol, minoxidil, chlordiazepoxide, diazepam, amitriptyline, and imipramine, cyclosporins, cyclosporine A, insulin, coichicine, glucagon, thyroid stimulating hormone, parathyroid hormone, pituitary hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatropin, oxytocin, vasopressin, prolactin, somatostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, interferons, interleukins, growth hormones such as human growth hormone, bovine growth hormone and porcine growth hormone, fertility inhibitors such as the prostaglandins, fertility promoters, growth factors, or human pancreas hormone releasing factor.

### Claim 13 (depends on 1)

The device of claim 1, wherein the expanded configuration resists passage through the pylorus prior to release of at least 40%, at least 50%, at least 70%, at least 80%, at least 90%, or at least 95% of the drug or diagnostic agent from the device.

### Claim 14 (depends on 1)

The device of claim 1, wherein the device comprises multiple subparts.

### Claim 15 (depends on 1)

The device of claim 1, wherein the device comprises more than 5 subparts.

### Claim 16 (depends on 1)

The device of claim 1, wherein the device separates into more than 5 subparts.

### Claim 17 (depends on 1)

A method of delivering an active or diagnostic agent to a subject's gastric environment for at least about 3 hours comprising orally administering the gastric retentive device of claim 1 to the subject.

### Claim 18 (depends on 17)

The method of claim 17, wherein the active or diagnostic agent is delivered to the subject's stomach for about 3 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 14 hours, about 16 hours, about 18 hours, about 20 hours, about 22 hours, about 24 hours, about 28 hours, about 30 hours, about 32 hours, about 34 hours, about 36 hours, about 40 hours, about 44 hours, about 48 hours, about 60 hours, or about 72 hours.

### Claim 19 (depends on 18)

The method of claim 18, wherein the administration is once daily, twice daily, or several times daily.

### Claim 20 (depends on 18)

The method of claim 18, wherein the administration frequency is once every 2 days to once every 14 days.
